LentiArray™ Cas9 Lentivirus
Product Image
Invitrogen™

LentiArray™ Cas9 Lentivirus

LentiArray Cas9 Lentivirus is provided as high-titer purified lentiviral particles and is an efficient method to drive high level Cas9 nuclease expression in a wide variety of cell types.
Have Questions?
產品號碼Quantity
A320691 mL
產品號碼 A32069
價格 (TWD)
73,290.00
온라인 행사
Ends: 31-Mar-2026
104,700.00
您節省 31,410.00 (30%)
Each
新增至購物車
Quantity:
1 mL
價格 (TWD)
73,290.00
온라인 행사
Ends: 31-Mar-2026
104,700.00
您節省 31,410.00 (30%)
Each
新增至購物車

The LentiArray Cas9 Lentivirus construct includes a human codon-optimized version of Cas9 with two nuclear localization signals to facilitate efficient delivery into the nucleus. The 1-mL size is designed to support studies utilizing a co-infection approach (Cas9 lentivirus + guideRNA lentivirus delivered together) with either the LentiArray CRISPR libraries or LentiArray gRNAs against single gene targets. LentiArray Cas9 Lentivirus is provided as ready-to-use lentivirus at a titer of 1 x 107 TU/mL.

Features include:

  • 1 mL high-titer lentiviral particles
  • Ready-to-use lentiviral particles at a titer of 1 x 107 TU/mL
  • EF-1a promotor that is highly effective in a wide variety of cell models
  • Create stable Cas9-expressing cell models for screening and focused CRISPR knockout studies
For Research Use Only. Not for use in diagnostic procedures.
規格
Delivery TypeLentiviral
For Use With (Application)CRISPR gene knockout
Product LineLentiArray
Product TypeCas9 Lentivirus
Quantity1 mL
Shipping ConditionDry Ice
PromoterEF-1a
Sample TypesiRNA
SpeciesHuman
Transfection TechniqueLentiviral transduction
Unit SizeEach
內容物與存放
1 x 1 mL. Store at -68 to -85°C.

引用資料與參考文獻 (1)

引用資料與參考文獻
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Authors:Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific ... More